safety concerns, and favorable benefit-to-harm ratios of other untried treatment options, the recommendation is against using pegloticase as first-line agent. should be considered in patients with CKD. While higher starting doses and CKD are associated with risk of AHS Administering concomitant antiinflammatory prophylaxis therapy (e.g., colchicine, nonsteroidal antiinflammatory drugs [NSAIDs], prednisone/ prednisolone) over no antiinflammatory prophylaxis therapy is strongly recommended. Based